Frameworks for Digital Advertising
Standards in Medicine.

United Kingdom · Advertising framework

Email, SMS and direct-message marketing for pharmacies and health retail in the United Kingdom

General market orientation, not campaign clearance. Research scope and dates

Product and service rules

Do not use waiting lists to promote unlicensed or prescription weight-loss medicines

Regulator guidance

Applies when: The offer concerns prescription or unlicensed weight-management medicines.

The June 2026 joint warning expressly identifies promotion of pipeline weight-management products, waiting lists and newly licensed oral GLP-1 medicines. Product novelty or a waiting-list sign-up does not remove the public-advertising restriction.

Assess the overall message of a clinic or pharmacy campaign, including indirect medicine references and its linked destination.

Sources: MHRA, ASA and GPhC — Warning on weight-management medicine promotion, 18 June 2026

Channel rules

Check the complete consumer-facing message

Regulator guidance

The DMCC consumer-protection regime addresses misleading claims, deceptive overall presentation and material omissions. Support factual statements with evidence and present important conditions in time for an informed decision. Review prices, qualifications and commercial intent alongside the health-sector requirements.

Sources: Unfair commercial practices: CMA207

Check subscriber type and the actual soft opt-in conditions

Regulator guidance

PECR normally requires consent for electronic marketing to individual subscribers unless an applicable soft opt-in is satisfied. Corporate subscribers follow a different route. Identify the sender and provide an opt-out. Social direct messages can be electronic mail; distinguish these from public posts.

Sources: Direct marketing using electronic mail

Separate promotional and service messages

Editorial recommendation

Review the rules for the actual delivery method: email, SMS and private social messages are not interchangeable. Keep the relevant permission record, accurate sender details and a working suppression process.

Campaign workflow

Pharmacies & Health Retail: prepare the review

Editorial recommendation

Separate promotion of the pharmacy from advertising of each medicine or other product. Verify online-supply and delivery permissions independently of advertising eligibility. Review price promotions and inducements under both retail and medicine rules.

Keep a traceable campaign decision

Editorial recommendation

Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.

Pre-publication checklist

  • Separate promotion of the pharmacy from advertising of each medicine or other product.
  • Verify online-supply and delivery permissions independently of advertising eligibility.
  • Review price promotions and inducements under both retail and medicine rules.
  • Record product or provider eligibility before approving claims.
  • Archive the final creative and its evidence, permissions and review decisions.
  • Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.

Scope and unresolved questions

  • Windsor medicine licensing and the GB/NI device distinction are now documented. Verify the exact authorisation, certificate validity, transitional eligibility and destination market. Food-claim transitions, other professional regulators and broadcaster-specific clearance remain separate checks.
  • This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates

Pharmacy promotion by email, SMS and direct messages in the United Kingdom needs separate decisions about the retailer, the advertised products and any online supply. Use this guide to keep medicine restrictions, seller permissions and promotional price mechanics in the same review.

Email, SMS and private platform messages can follow different permission rules. Identify the delivery technology and the recipient relationship, then review the promotional content and withdrawal process separately.

Sources checked 2026-10-24 · Editorial research · Legal review pending

General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.

Coverage: National baseline and category-specific review routes; not an exhaustive compliance opinion

How to use this national baseline

Editorial overview

This framework combines researched national rules with editorial review steps. UK advertising baseline with a required Great Britain versus Northern Ireland product-regime check. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.

The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.

Your next step: choose a local partner

Use this framework to brief qualified local legal and regulatory specialists. Ask them to verify current requirements and assess your specific product, service and campaign before acting.

Sources

  1. Unfair commercial practices: CMA207

    Competition and Markets Authority · regulator guidance · checked 2026-10-24

    Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.

  2. Direct marketing using electronic mail

    Information Commissioner’s Office · regulator guidance · checked 2026-10-24

    Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.

  3. MHRA, ASA and GPhC — Warning on weight-management medicine promotion, 18 June 2026

    MHRA / ASA / GPhC · regulator guidance · checked 2026-10-25

    Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.

From framework to action

Local expertise in United Kingdom

Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in United Kingdom.

Medical & health marketing

No partners listed in this category yet.

Marketing & sales advisory

No partners listed in this category yet.

Business & project coordination

No partners listed in this category yet.

Browse partners in United Kingdom

Join the local partner directory

Would you like your company to be listed?

Talk to us about the terms of a listing. Leave your details and we will get in touch.

Publicity@fdasm.com

Contact details for a partner listing enquiry

We use your details to respond to your enquiry and discuss a listing. Submitting the form does not automatically add your company to the directory. Read our Privacy & cookies policy. Privacy contact: Publicity@fdasm.com.